Bisphosphonates in lung cancer: More than a palliative therapy?

Seminars in Oncology

Volumn 37, Issue SUPPL., 2010, Pages

  Jahanzeb, Mohammad ^a,c   Hirsh, Vera ^b  

^a Boca Raton Comprehensive Cancer Center   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE METABOLISM; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE SCINTISCANNING; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FLU LIKE SYNDROME; HEALTH CARE COST; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SOLID TUMOR; TREATMENT OUTCOME;

EID: 77955433435     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.06.004     Document Type: Article

References (45)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. T.E. Stinchcombe, C.B. Lee, and M.A. Socinski Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status Clin Lung Cancer 7 2006 S111 S117
3. M. Horner, L. Ries, and M. Krapcho, et al. SEER Cancer Statistics Review, 1975-2006 Surveillance Epidemiology and End Results http://seer.cancer.gov/csr/ 1975-2006/. Modified 2009 Accessed April 14, 2009.
4. R.E. Coleman Bisphosphonates: clinical experience Oncologist 9 2004 14 27
5. V. Hirsh Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer Clin Lung Cancer 10 2009 223 229
6. A. Tsuya, T. Kurata, K. Tamura, and M. Fukuoka Skeletal metastases in non-small cell lung cancer: a retrospective study Lung Cancer 57 2007 229 232
7. T.E. Delea, J. McKiernan, and J. Brandman, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer J Thorac Oncol 1 2006 571 576
8. R.D. Pockett, D. Castellano, P. McEwan, A. Oglesby, B.L. Barber, and K. Chung The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain Eur J Cancer Care (Engl) 2009 Epub
9. I. Sekine, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, and T. Tamura Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy Lung Cancer 65 2009 219 222
10. M.T. Groot, C.G. Boeken Kruger, R.C. Pelger, and C.A. Uyl-de Groot Costs of prostate cancer, metastatic to the bone, in the Netherlands Eur Urol 43 2003 226 232
11. B.E. Hillner, J.C. Weeks, C.E. Desch, and T.J. Smith Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis J Clin Oncol 18 2000 72 79
12. T. Delea, C. Langer, and J. McKiernan, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer Oncology 67 2004 390 396
13. N. Saba, and F. Khuri The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer Part 2: Clinical studies and economic analyses Oncology 68 2005 18 22
14. G. D'Addario, and E. Felip Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 suppl 4 2009 68 70
15. D.G. Pfister, D.H. Johnson, and C.G. Azzoli, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
16. National Comprehensive Cancer Network Inc. NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer. V.2.2010 www.nccn.org Accessed April 14, 2010
17. S. Erturan, M. Yaman, G. Aydin, I. Uzel, B. Musellim, and K. Kaynak The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer Chest 127 2005 449 454
18. L. Iordanidou, E. Trivizaki, and S. Saranti, et al. Is there a role of whole body bone scan in early stages of non small cell lung cancer patients J BUON 11 2006 491 497
19. H. Schirrmeister, C. Arslandemir, and G. Glatting, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer Eur J Nucl Med Mol Imaging 31 2004 964 968
20. F. De Marinis, W. Eberhardt, and P.G. Harper, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel J Thorac Oncol 4 2009 1280 1288
21. Nackaerts KL, Langer CJ, Harper PG, Manegold C, Ettinger DS, Kosmidis PA. International consensus panel recommendations for the diagnosis of bone metastases from lung cancer. Presented at: 1st European Lung Cancer Conference; European Society for Medical Oncology-International Association for the Study of Lung Cancer; 2008 April 23; Geneva, Switzerland.
22. R.E. Coleman Skeletal complications of malignancy Cancer 80 1997 1588 1594
23. P.A. Kvale, P.A. Selecky, and U.B. Prakash Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 132 2007 368S 403S
24. L.S. Rosen, D. Gordon, and N.S. Tchekmedyian, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial Cancer 100 2004 2613 2621
25. A. Piga, R. Bracci, and B. Ferretti, et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy J Exp Clin Cancer Res 17 1998 213 217
26. M. Kiagia, E. Karapanagiotou, and A. Charpidou, et al. Rapid infusion of ibandronate in lung cancer patients with bone metastases Anticancer Res 26 2006 3133 3136
27. K. Mystakidou, E. Stathopoulou, E. Parpa, V. Kouloulias, E. Kouskouni, and L. Vlahos Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease J Cancer Res Clin Oncol 134 2008 1303 1310
28. K. Kritikos, P. Heras, A. Hatzopoulos, S. Karagiannis, and D. Mitsibounas Ibandronate and pamidronate in patients with bone metastases from breast or lung cancer: a comparative study [abstract] J Clin Oncol (Meeting Abstracts) 23; 2005 8283
29. B. Rankovic, and V. Mrdja [Use of disodium pamidronate in patients with bone metastases in patients with pulmonary carcinoma] Vojnosanit Pregl 59 2002 33 36
30. K. Zarogoulidis, E. Boutsikou, and P. Zarogoulidis, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis Int J Cancer 125 2009 1705 1709
31. H.T. Hatoum, S.J. Lin, M.R. Smith, V. Barghout, and A. Lipton Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database Cancer 113 2008 1438 1445
32. Hatoum HT, Lin S, Lipton A, Guo A, Smith MR. Persistency on monthly zoledronic acid impacts risk and frequency of skeletal complications and follow-up duration in lung cancer patients. Presented at: 13th World Conference on Lung Cancer; 2009 July 31; San Francisco, CA.
33. C. Langer, and V. Hirsh Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates Lung Cancer 67 2010 4 11
34. G.D. Roodman Biology of osteoclast activation in cancer J Clin Oncol 19 2001 3562 3571
35. K. Fizazi, J. Yang, and S. Peleg, et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts Clin Cancer Res 9 2003 2587 2597
36. D. Henry, R. von Moos, and S. Vadhan-Raj, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma [abstract] Eur J Cancer Suppl 7 2009 12
37. A. Lipton, R. Cook, and F. Saad, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Cancer 113 2008 193 201
38. V. Hirsh, P.P. Major, and A. Lipton, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity J Thorac Oncol 3 2008 228 236
39. Costa L, Cook R, Body JJ, et al. Zoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption. Presented at: The IX International Meeting on Cancer Induced Bone Disease; 2009 October 28; Arlington, VA.
40. K.J. Pandya, A. Gajra, G.M. Warsi, E. Argonza-Aviles, S.G. Ericson, and A.J. Wozniak Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer Lung Cancer 67 2010 330 338
41. K. Mystakidou, E. Katsouda, E. Parpa, A. Kelekis, A. Galanos, and L. Vlahos Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline Med Oncol 22 2005 195 201
42. Scagliotti G, Manegold C, de Marinis F, et al. Evaluating the efficacy of zoledronic acid for the prevention of disease progression in patients with non-small cell lung cancer. Presented at: Joint European Cancer Organisation (ECCO) 15 - 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress; 2009 September 20; Berlin, Germany.
43. M. Aapro, P.A. Abrahamsson, and J.J. Body, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 2008 420 432
44. C.I. Ripamonti, M. Maniezzo, and T. Campa, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates The experience of the National Cancer Institute of Milan Ann Oncol 20 2009 137 145
45. A.O. Hoff, B.B. Toth, and K. Altundag, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 2008 826 836